Transthyretin (ATTR) Amyloidosis
View the latest scientific data presented at congress events in the past 2 years and discover peer-reviewed publications related to ATTR Amyloidosis.
The information on this page pertains to select congress and publication resources. It is not intended to serve as a comprehensive list of all congress and publications resources.
Congresses
Transthyretin Amyloidosis (ATTR)
American Association of Neuromuscular and Electrodiagnostic Medicine (AANEM) 2024
Transthyretin Amyloidosis (ATTR)
Heart Failure Society of America (HFSA) 2024
Transthyretin Amyloidosis (ATTR)
European Society of Cardiology (ESC) 2024
Publications
Transthyretin Amyloidosis (ATTR)
Treatment with vutrisiran in people with transthyretin amyloidosis with cardiomyopathy: A plain language summary
Future Cardiology
Transthyretin Amyloidosis (ATTR)
Diagnosis of hereditary transthyretin amyloidosis in patients with suspected chronic inflammatory demyelinating polyneuropathy unresponsive to intravenous immunoglobulins: results of a retrospective study
Orphanet Journal of Rare Diseases
Transthyretin Amyloidosis (ATTR)
Impact of Vutrisiran on Functional Capacity and Quality of Life in Transthyretin Amyloidosis with Cardiomyopathy
Journal of the American College of Cardiology
Transthyretin Amyloidosis (ATTR)
Impact of Heart Failure Severity on Vutrisiran Efficacy in Transthyretin Amyloidosis with Cardiomyopathy
Journal of the American College of Cardiology
Transthyretin Amyloidosis (ATTR)
Worsening of Heart Failure in Outpatients With Transthyretin Amyloidosis and Cardiomyopathy in the APOLLO-B Trial
Journal of the American College of Cardiology
Transthyretin Amyloidosis (ATTR)
Five-Year Results With Patisiran for Hereditary Transthyretin Amyloidosis With Polyneuropathy
JAMA Neurology
